CAMRIS International, LLC, an HJF Company, its involvement in COVID-19 vaccine research by the Walter Reed Army Institute of Research (WRAIR).
As recently reported in a leading scientific journal, the Army’s development of a COVID-19 vaccine using a Spike Ferritin Nanoparticle (SpFN) platform showed encouraging preclinical results.
Also, as reported in The Hill, the developed vaccine may also have broader effectiveness against SARS-origin viruses and emerging variants. That SpFN platform is manufactured in WRAIR’s Pilot Bioproduction Facility (PBF) in Silver Spring, MD. The PBF is the only cGMP-compliant pharmaceutical manufacturing plant in the U.S. Army and the Department of Defense.
CAMRIS currently supports operation of the WRAIR PBF under an Other Transaction Authority type agreement and is a key manufacturing partner. “CAMRIS is particularly proud to support WRAIR’s Pilot Bioproduction Facility in combatting the scourge of COVID-19,” said Brad Sepp, MS, CAMRIS’ Vice President of Programs and Pilot Bioproduction Facility Program Manager.